EFFECT OF ANTIAGGREGANT ON OCCLUSION OF SAPHENOUS GRAFT CORONARY BYPASS

1987 ◽  
Author(s):  
E Lavenne-Pardonge ◽  
C Col-De Beys ◽  
R Dion ◽  
R Ponlot ◽  
M Moriau
Keyword(s):  
Placebo Group ◽  
Coronary Bypass ◽  
Arterial Disease ◽  
Treated Group ◽  
Double Blind Study ◽  
Careful Study ◽  
Double Blind ◽  
Normal Limits ◽  
Group 2 ◽  
Long Acting

Double blind study on 49 patients, 24receiving aspirine-dipyri-damole, 25 a placebo. In both groups 20 patients were followed during one year. The two groupsdid not differ according to age, sex and number of coronary bypass. In all the patients, Calparin (3 x 5000 U/day) was injected subcutanously the day before andthe 7 days after surgery. In the first group dipyridamole (25 mg/ kg) was injected during the same period. The second group received a placebo IV injection. Thereafter long acting dipyridamole (400 mg/day) and aspirin (200 mg/day) were given orally in the first group, placebo in the second one. Cardiac follow-up included E.C.G. and thallium at maximum exercise. Coronarography was performed only incase of reappearence of chest pain. No difference was found between the two groups for the coagulation parameters duringthe whole year of study. Statistically significant differences between the two groups were found during the same period for β-thromboglobulin, fibrino-peptide A and the ratio Δ+ βTG/Δ+ FPA. Plateletactivity, elevated in the placebo group, was kept in normal limits in the treated group. During the two first months for the placebo and during the first month for the treated group the ratio Δ+ βTG/Δ+ FPA decreased in all patients showing the importance at this time of plasmatic hypercoagulability compared to platelet hyperactivity. During the 12 months of the study 5 thrombotic accidents (25 %) were noted in the placebo group (2 myocardial infarctions, 2 occlusions of bypass, 1 case of cerebral arterial disease) and 2 (10 % in the treated group) (1 postoperative death, 1 myocardial infarction) (NS ; p =0,21). Our results lead to two conclusions : 1) Platelet antiaggregants may influencethe permeability of saphenous .graft coronary bypass. A careful study of platelet acti-r vity with eventual change of the drug used may improve the late resultsof surgery. 2) Association of anticoagulant therapy (anti-vitamin K) during the two first months after surgery could also be useful.

The influence of atorvastatin on walking performance in peripheral arterial disease

VASA ◽  
2009 ◽  
Vol 38 (2) ◽  
pp. 155-159 ◽  
Author(s):  
Bregar ◽  
Poredoš ◽  
Šabovič ◽  
Jug ◽  
Šebeštjen
Keyword(s):  
Peripheral Arterial Disease ◽  
Ldl Cholesterol ◽  
Arterial Disease ◽  
Treated Group ◽  
Walking Distance ◽  
Control Group ◽  
Double Blind Study ◽  
Double Blind ◽  
Walking Performance ◽  
Peripheral Arterial

Background: Recently it has been shown that statins can improve walking distance in patients with peripheral arterial disease. We examined whether statins used in moderate dosages with the aim of reaching the target levels for hypercholesterolemia could improve walking performance in patients with peripheral arterial disease. Patients and methods: 37 patients with hypercholesterolemia (LDL cholesterol = 3.46 ± 0.13 mmol/l), who had previously not been treated by statins, were randomized in a double-blind study to a group receiving either atorvastatin at 20 mg/day (N = 20) or placebo (N = 17). All patients had stable intermittent claudication (Fontaine class IIa or IIb). At baseline, after one and three months the pain-free walking distance was measured in all patients. Results: After 3 months patients in the treated group had reached target cholesterol values (LDL cholesterol = 2,34 ± 0.9 mmol/l), whereas no significant change in lipids was observed in the control group. The ankle-brachial pressure index (ABPI) did not change significantly in either group. After 3 months the pain-free walking distance was increased significantly (p < 0.001), but similarly in both groups (at entry: 56 (53–108) m vs 53 (53–106) m; after 3 months: 79 (53–108) m vs 106 (66–159) m, for the treated and placebo group, respectively). Therefore this effect had to be attributed to regular exercise and not to statin use. Conclusions: Our results show that routine treatment with statin (atorvastatin 20 mg/day), which is effective in reducing the level of cholesterol, does not produce an improvement in walking performance in patients with peripheral arterial disease.

Amphetamine Withdrawal: II. A Placebo-Controlled, Randomised, Double-Blind Study of Amineptine Treatment

1999 ◽  
Vol 33 (1) ◽  
pp. 94-98 ◽  
Author(s):  
Manit Srisurapanont ◽  
Ngamwong Jarusuraisin ◽  
Jaroon Jittiwutikan
Keyword(s):  
Placebo Group ◽  
Therapeutic Effects ◽  
Double Blind Study ◽  
Double Blind ◽  
Intention To Treat ◽  
Parallel Group ◽  
Amphetamine Withdrawal ◽  
The Mean ◽  
Group 2 ◽  
Treat Analysis

Objective: The aim of this study was to examine the benefits of amineptine, a dopamine agonist antidepressant, in treating amphetamine withdrawal. Method: Inpatients with amphetamine withdrawal were recruited to participate in this placebo-controlled, randomised, double-blind, parallel group, 2-week comparison of amineptine and placebo treatments. The treatment effects were evaluated by means of the self-administered Amphetamine Withdrawal Questionnaire (AWQ) and the interviewer-administered Clinical Global Impression (CGI) scale. An intention-to-treat analysis was applied to evaluate the therapeutic effects at the end of week 1 and week 2. Results: Twenty-two patients took part in each treatment group. The week-1 and week-2 intention-to-treat analyses showed that the mean AWQ reversed vegetative scores (combined scores of decreased energy, increased appetite and craving for sleep items) of the amineptine group were significantly lower than those of the placebo group. The general condition of the amineptine group assessed by CGI also significantly improved at the end of week 2. Although the discontinuation rate due to dissatisfaction with treatment of amineptine group (1/21) was much lower than that of placebo group (6/22), those rates were not significantly different (p = 0.09). Conclusions: Amineptine is specifically effective for treating a major component of amphetamine withdrawal: a reversed vegetative syndrome. Although more than 2 weeks of amineptine treatment may contribute further benefits, both risks and benefits should be taken into account in doing so.

The Effect of Silicol Gel Compared with Placebo on Papulopustular Acne and Sebum Production. A Double-Blind Study

1996 ◽  
Vol 24 (4) ◽  
pp. 340-344 ◽  
Author(s):  
A Lassus
Keyword(s):  
Placebo Group ◽  
Treated Group ◽  
Double Blind Study ◽  
Concomitant Treatment ◽  
Double Blind ◽  
Area 5 ◽  
Significant Difference ◽  
The Face ◽  
Sebum Production ◽  
The Mean

Altogether 30 patients (19 females and 11 males), mean age 19 years, were divided randomly into two groups. All patients had chronic papulopustular acne of the face. A total of 15 patients were treated topically with Silicol gel for 20 min twice daily for 6 weeks and the remaining 15 patients were treated with a placebo gel in a similar fashion. A clinical evaluation was carried out at baseline, and after 2, 4 and 6 weeks of treatment. The clinical variables evaluated were as follows: number of comedones, papules, pustules and cysts on a standard area of the left cheek (area 5 × 5 cm) and measurement of sebum production on the same area by the use of Sebumeter SM 810 PC (Courage and Khazaka, Ltd, Germany). No concomitant treatment was allowed during the study period. One patient using Silicol gel withdrew after 2 weeks of treatment because of severe irritation of the facial skin, leaving 29 patients who could be evaluated. In the active group, the number of comedones decreased from a mean of 48.5 to 15.1 after 6 weeks of treatment. The corresponding figures for papules were 10.7 and 1.0, for pustules 6.8 and 0, and for cysts 0.6 and 0. In the placebo group no improvement could be observed. There was a highly significant difference in efficacy between the two groups ( P < 0.001) in favour of the actively treated group. The mean sebum index was 193 at baseline and 88 after 6 weeks. Correspondingly, in the placebo group the mean sebum index at baseline was 187 and after 6 weeks 179. This difference between the two groups was also statistically significant ( P < 0.001). After a short follow-up period (3 months) no deterioration was observed in the 14 ‘active’ patients, showing either complete cure or improvement.

Double-Blind Comparison of Single Oral Doses of Oxaprozin, Aspirin, and Placebo for Relief of Post-Operative Oral Surgery Pain

1983 ◽  
Vol 11 (5) ◽  
pp. 308-314 ◽  
Author(s):  
Leo Winter ◽  
Arthur Post
Keyword(s):  
Placebo Group ◽  
Pain Relief ◽  
Oral Surgery ◽  
Treated Group ◽  
Double Blind Study ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Surgical Pain ◽  
Blind Comparison ◽  
Oral Doses

The safety and efficacy of single oral doses of Oxaprozin (1200 mg), aspirin (650 mg), and placebo were compared in an 8-hour double-blind study of 105 patients with moderate to severe post-operative dental-surgical pain. As measured by mean and cumulative mean scores obtained with the pain intensity and verbal pain relief scales, both active drugs produced significantly (p < 0·05) more analgesia than did placebo. A significantly (p < 0·05) greater proportion of patients reported effective (moderate or better) pain relief in the Oxaprozin and aspirin groups than in the placebo group at 2, 3, and 4 hours; significant (p < 0·05) differences between the Oxaprozin and placebo groups continued for the entire 8 hours. Oxaprozin provided more pain relief than aspirin during the latter part of the study. There were no statistically significant differences, however, in any of the efficacy assessments between the Oxaprozin and aspirin groups. By the end of the 8-hour observation, significantly (p < 0·01) fewer patients taking Oxaprozin (27%) than placebo (60%) were considered treatment failures and needed a replacement analgesic. Of those taking aspirin, 41% were treatment failures, not statistically different from the proportion of treatment failures with placebo. Adverse effects were infrequent, mild, comparable between the active treatment and placebo groups, and not definitely related to drug therapy. Oxaprozin provided greater pain relief than placebo and was comparable to aspirin during the first 4 hours of the evaluation; thereafter, greater pain relief occurred in the oxaprozin-treated group than either the aspirin- or placebo-treated group.

The Effect of Warfarin Sodium on the Duration of Platelet Aggregation

1967 ◽  
Vol 18 (03/04) ◽  
pp. 766-778 ◽  
Author(s):  
H. J Knieriem ◽  
A. B Chandler
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Platelet Rich Plasma ◽  
Healthy Adults ◽  
Double Blind Study ◽  
Double Blind ◽  
Warfarin Sodium

SummaryThe effect of the administration of warfarin sodium (Coumadin®) on the duration of platelet aggregation in vitro was studied. Coumadin was given for 4 consecutive days to 10 healthy adults who were followed over a period of 9 days. The duration of adenosine diphosphate-induced platelet aggregation in platelet-rich plasma, the prothrombin time, and the platelet count of platelet-rich plasma were measured. Four other healthy adults received placebos and participated in a double-blind study with those receiving Coumadin.Although administration of Coumadin caused a prolongation of the prothrombin time to 2 or 21/2 times the normal value, a decrease in the duration of platelet aggregation was not observed. In most individuals who received Coumadin an increase in the duration of platelet aggregation occurred. The effect of Coumadin on platelet aggregation was not consistently related to the prothrombin time or to the platelet count. In the placebo group there was a distinct relation between the duration of platelet aggregation and the platelet count in platelet-rich plasma.The mean increase in the duration of platelet aggregation when compared to the control value before medication with Coumadin was 37.7%. In the placebo group there was a mean increase of 8.4%. The difference between the two groups is significant (p <0.001). Increased duration of platelet aggregation also occurred in two individuals who received Coumadin over a period of 10 and 16 days respectively.

scholarly journals Efficacy of Calcipotriol 0.005% Ointment for Uremic Xerosis with Pruritus in Chronic Kidney Diseases Undergoing Hemodialysis Patients: Randomized Double Blind Clinical Trial

2021 ◽  
Vol 5 (6) ◽  
pp. 531-539
Author(s):  
Widyastuti ◽  
Yulia Farida Yahya ◽  
Suroso Adi Nugroho ◽  
Soenarto Kartowigno ◽  
M. Izazi Hari Purwoko ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Placebo Group ◽  
Visual Analog Scale ◽  
Kidney Diseases ◽  
Double Blind Study ◽  
Surface Lipid ◽  
Dry Skin ◽  
Analog Scale ◽  
Double Blind ◽  
Skin Score

Introduction: Uremic xerosis with pruritus (UXP) is a chronic cutaneous complication among patients undergoing maintenance renal dialysis. Uremic xerosis level is directly related with pruritus severity or vice versa. Uremic xerosis with pruritus may lead to discomfort and negative psychological effect. The ethiopathogenesis still unknown, Most of treatments are empirical, and there is no effective and safe therapy. Emollient has not been effective enough to improve quality of life. There is some report about efficacy of topical vitamin D in xerosis and chronic pruritus. Objective: We evaluate the efficacy of calcipotriol 0.005% ointment for uremic xerosis and uremic pruritus in chronic kidney disease patients undergoing hemodialysis. Material & methode: Sixty two patients with UXP were enrolled, randomized double blind study. Patients were divided to two group, calcipotriol 0.005% ointment group or placebo. In baseline, patients were instructed to apply twice daily for four weeks. We assesesment the efficacy and safety of calcipotriol 0.005% ointment and placebo after 2nd and 4th weeks treatment using overall dry skin score (ODSS), visual analog scale (VAS), corneometer and sebumeter. We also assessed adverse effect and tolerance this drugs using visual assessment scale. Results: Overall dry skin score (ODSS) and visual analog scale (VAS) significantly decreased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Skin hydration level based on Corneometer score and skin surface lipid based on Sebumeter score was significantly increased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Cure rate and clinical improvement for calcipotriol 0.005% ointment group was significantly higher than placebo group. There was no adverse effect between two groups after treatment. Conclusion: calcipotriol 0.005% ointment is effective than placebo and can be used as alternative or adjuctive treatment and safe and tolerance for UXP.

scholarly journals Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses

2018 ◽  
Vol 4 (2) ◽  
pp. 00119-2017 ◽  
Author(s):  
David M.G. Halpin ◽  
Ruby Birk ◽  
Noushin Brealey ◽  
Gerard J. Criner ◽  
Mark T. Dransfield ◽  
...  
Keyword(s):  
Disease Severity ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Forced Expiratory Volume ◽  
Phase Iii ◽  
Chronic Obstructive ◽  
Double Blind Study ◽  
Double Blind ◽  
Subgroup Analyses ◽  
Long Acting

Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear.FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg using the Ellipta inhaler with twice-daily budesonide/formoterol (BUD/FOR) 400/12 µg using the Turbuhaler. Subgroup analyses of forced expiratory volume in 1 s (FEV1), St George's Respiratory Questionnaire (SGRQ) Total score and exacerbation rates were carried out. Subgroups were defined by COPD medication at screening (ICS+LABA, BUD+FOR, ICS+LABA+LAMA, LAMA alone, tiotropium alone and LAMA+LABA), by disease severity (lung function and exacerbations) and by exacerbation history (exacerbation severity and frequency).In the intent-to-treat population (n=1810) at week 24, FF/UMEC/VI (n=911) versus BUD/FOR (n=899) improved FEV1 and SGRQ Total score and reduced mean annual exacerbation rates in all disease severity and exacerbation history subgroups. FF/UMEC/VI versus BUD/FOR improved FEV1 and SGRQ Total score in all medication subgroups and reduced mean annual exacerbation rates in all medication subgroups, except LAMA+LABA. Adverse events were similar across subgroups.These findings support the benefit of FF/UMEC/VI compared with dual ICS/LABA therapy in patients with symptomatic COPD regardless of disease severity or prior treatment and may help to inform clinical decision making.

STUDIES OF TOCOPHEROL DEFICIENCY IN INFANTS AND CHILDREN

PEDIATRICS ◽  
1961 ◽  
Vol 27 (4) ◽  
pp. 578-588
Author(s):  
Stanley Levin ◽  
Mordecai H. Gordon ◽  
Harold M. Nitowsky ◽  
Carmen Goldman ◽  
Paul di Sant'Agnese ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Muscle Strength ◽  
Treated Group ◽  
Muscle Disease ◽  
Tocopheryl Acetate ◽  
Double Blind Study ◽  
Double Blind ◽  
Quantitative Measurements ◽  
Clinical Conditions ◽  
Group Serum

A bulb ergographic method for estimating muscle strength was modified to permit quantitative measurements. Studies in a group of 13 convalescent children without muscle disease established the reliability of the method for repeated observations. Forty-five patients with cystic fibrosis, whose clinical conditions appeared stable, were accepted in a double-blind study comparing the effect of tocopherol or a placebo on serum tocopherol, S-GOT, weight gain, subjective improvement, and muscle strength as measured by the ergograph. Measurements were made at the beginning of the study, and 2 and 6 months after beginning tocopheryl acetate (10 mg/kg/day) or placebo therapy. Although statistically significant increases in serum tocopherol, weight, muscle strength, and clinical improvement were found at 2 and 6 months after beginning of the study, there were no significant differences between the two groups, except in serum content of tocopherol. In the tocopherol treated group, serum tocopherol became normal (0.83 to 1.05 mg/100 ml), but remained low (0.20 to 0.33 mg/100 ml) in the placebo group. Although the present study did not demonstrate a clinical functional effect of tocopherol therapy in patients with cystic fibrosis, its administration is recommended because of previously reported biochemical and pathologic evidence of vitamin E deficiency in these subjects.

Adding herbal extracts to silicone gel on post-sternotomy scar: a prospective randomised double-blind study

2020 ◽  
Vol 29 (Sup4) ◽  
pp. S36-S42
Author(s):  
Palakorn Surakunprapha ◽  
Kengkart Winaikosol ◽  
Bowornsilp Chowchuen ◽  
Kriangsak Jenwitheesuk ◽  
Kamonwan Jenwitheesuk
Keyword(s):  
Aloe Vera ◽  
Median Sternotomy ◽  
Centella Asiatica ◽  
Herbal Extract ◽  
Double Blind Study ◽  
Herbal Extracts ◽  
Double Blind ◽  
Silicone Gel ◽  
Group 2 ◽  
Group 1

Objective: Silicone gel has been shown effective in improving healing post-sternotomy scars. It remains to be determined whether adding herbal extracts to the gel would augment the healing effect. Method: After median sternotomy, patients were randomised into two groups. Group 1: topical silicone gel plus herbal extract gel (Allium cepa, Centella Asiatica, Aloe vera and Paper Mulberry) and Group 2: silicone gel. Patients were treated for six months. The postoperative scars were assessed at three and six months by plastic surgeons using the Vancouver Scar Scale (VSS) and the patient assessment scar scale. Results: Each group comprised 23 patients (n=46 in total). The VSS was significantly lower in Group 1 than in Group 2 (p=0.018 and p=0.051, respectively). In Group 1, the four differences from baseline were vascularity scores at three and six months (–0.391, p=0.025; –0.435, p=0.013, respectively), and pigmentation scores at three and six months (–0.391, p=0.019; –0.609, p=0.000, respectively). In Group 2, differences from baseline were the pigmentation and vascularity score at six months (–0.6609, p=0.000; –0.348, p=0.046, respectively). Conclusion: Our results suggest, post-sternotomy scars trend to have better vascularity and pigmentation when treated with silicone gel plus herbal extracts.

Sign in / Sign up

Export Citation Format

Share Document